Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Nov 3;6(11):e012356.
doi: 10.1136/bmjopen-2016-012356.

ImmunoglobuliN in the Treatment of Encephalitis (IgNiTE): Protocol for a Multicentre Randomised Controlled Trial

Affiliations
Free PMC article
Randomized Controlled Trial

ImmunoglobuliN in the Treatment of Encephalitis (IgNiTE): Protocol for a Multicentre Randomised Controlled Trial

M A Iro et al. BMJ Open. .
Free PMC article

Abstract

Introduction: Infectious and immune-mediated encephalitides are important but under-recognised causes of morbidity and mortality in childhood, with a 7% death rate and up to 50% morbidity after prolonged follow-up. There is a theoretical basis for ameliorating the immune response with intravenous immunoglobulin (IVIG), which is supported by empirical evidence of a beneficial response following its use in the treatment of viral and autoimmune encephalitis. In immune-mediated encephalitis, IVIG is often used after a delay (by weeks in some cases), while diagnosis is confirmed. Wider use of IVIG in infectious encephalitis and earlier use in immune-mediated encephalitis could improve outcomes for these conditions. We describe the protocol for the first ever randomised control trial of IVIG treatment for children with all-cause encephalitis.

Methods and analysis: 308 children (6 months to 16 years) with a diagnosis of acute/subacute encephalitis will be recruited in ∼30 UK hospitals and randomised to receive 2 doses (1 g/kg/dose) of either IVIG or matching placebo, in addition to standard treatment. Recruitment will be over a 42-month period and follow-up of each participant will be for 12 months post randomisation. The primary outcome is 'good recovery' (score of 2 or lower on the Glasgow Outcome Score Extended-paediatric version), at 12 months after randomisation. Additional secondary neurological measures will be collected at 4-6 weeks after discharge from acute care and at 6 and 12 months after randomisation. Safety, radiological, other autoimmune and tertiary outcomes will also be assessed.

Ethics and dissemination: This trial has been approved by the UK National Research Ethics committee (South Central-Oxford A; REC 14/SC/1416). Current protocol: V4.0 (10/03/2016). The findings will be presented at national and international meetings and conferences and published in peer-reviewed journals.

Trial registration numbers: NCT02308982, EudraCT201400299735 and ISRCTN15791925; Pre-results.

Keywords: ADEM; GOSE-Peds; autoimmune; encephalitides; immune-mediated.

Conflict of interest statement

CSL Behring have provided the study IMP (IVIG) and funded manufacture of placebo and the supply and distribution of IMP and placebo. AJP reports grants from NIHR EME programme, during the conduct of the study. The University of Oxford and AV hold patents for VGKC-complex antibody tests, licensed to Euroimmun AG, and receive royalties. The neuroimmunology work in the described trial is funded through the MRC/NIHR grant. MA serves on the data safety monitoring board for a study sponsored by Neurim Pharmaceuticals and is on the editorial advisory board for the International Journal of Language and Communication Disorders. MAI and LW report salary from the NIHR EME grant. ML has received consultation fees from CSL Behring, travel grants from Merck Serono and been awarded educational grants to organise meetings by Novartis, Biogen Idec, Merck Serono and Bayer. MS reports grants from Pfizer, outside the submitted work. TS is supported by the National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections at Liverpool. AE, LW, L-MY, MP, MS, RK and WKC have nothing to disclose.

Figures

Figure 1
Figure 1
Flow chart showing process of participant recruitment.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Venkatesan A, Tunkel AR, Bloch KC et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 2013;57:1114–28. 10.1093/cid/cit458 - DOI - PMC - PubMed
    1. Granerod J, Cousens S, Davies NW et al. New estimates of incidence of encephalitis in England. Emerging Infect Dis 2013;19:1455–62. 10.3201/eid1909.130064 - DOI - PMC - PubMed
    1. Kneen R, Michael BD, Menson E et al. Management of suspected viral encephalitis in children—Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group national guidelines. J Infect 2012;64:449–77. 10.1016/j.jinf.2011.11.013 - DOI - PubMed
    1. Pillai SC, Hacohen Y, Tantsis E et al. Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome. Pediatrics 2015;135:e974–84. 10.1542/peds.2014-2702 - DOI - PubMed
    1. Graus F, Titulaer MJ, Balu R et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391–404. 10.1016/S1474-4422(15)00401-9 - DOI - PMC - PubMed

Publication types

Substances

Supplementary concepts

Feedback